Baker Botts (Washington)

Christopher Wilson

Baker Botts (Washington)
Senior Associate

Christopher Wilson is an associate in Baker Botts’ Antitrust and Competition Practice group. His practice focuses on civil antitrust, intellectual property, and other complex commercial actions. Mr. Wilson has extensive experience in representing litigants from complaint filing through trial, as well as in advising corporate clients on a variety of antitrust matters, particularly with respect to parent/subsidiary issues, resale price maintenance, the Robinson-Patman Act, and compliance matters. He has represented and advised clients in a number of industries, including industrial manufacturing, telecommunications, pharmaceuticals, retail, and healthcare manufacturing. Prior to joining Baker Botts, Mr. Wilson was an associate at an international law firm, where he practiced in antitrust and intellectual property litigation. He has been a key member of legal teams for Fortune 500 clients defending against Sherman Act class action claims, including in cases that were granted favorable judgments at the motion to dismiss and summary judgment stages. He also has extensive experience in representing generic pharmaceutical manufacturers in Hatch-Waxman Act litigation, as well as in defending sham litigation claims in patent infringement and antitrust actions. In each of these cases, Mr. Wilson was deeply involved in setting case strategy, preparing dispositive and other critical filings, managing discovery, taking depositions, and negotiating with opposing counsel. Mr. Wilson graduated from Stanford Law School, where he served as President of the Stanford Black Law Students Association and participated in legal clinics directed to criminal defense and public education law. He received his undergraduate degree from Penn State University, where he was a Schreyer Honors Scholar and played running back and fullback for the university’s football team.


Linked authors

Baker Botts (New York)
Baker Botts (London)
Baker Botts (Washington)
Baker Botts (Washington)
Baker Botts (Washington)


885 Bulletin

William Lavery, Christine Ryu-Naya, Christopher Wilson The US Court of Appeals for the Fifth Circuit upholds the FTC’s ruling regarding an unlawful pay-for-delay agreement in the pharmaceutical sector (Endo / Impax)


On April 13, 2021, the U.S. Court of Appeals for the Fifth Circuit upheld the Federal Trade Commission’s (“FTC” or “Commission”) ruling that the “reverse-payment” settlement agreement between Endo Pharmaceuticals Inc. (“Endo”) and Impax Laboratories LLC (“Impax”) violated federal antitrust laws. The (...)

Peter Huston, Joseph Ostoyich, Scott Keller, Christopher Wilson The US Supreme Court increases the risk that online marketplaces with exclusive rights to third-party products will not have a defense under the “indirect purchaser” doctrine (Apple / Pepper)


On May 13, 2019, the U.S. Supreme Court issued a major antitrust decision in Apple v. Pepper, which could have far-reaching implications for retailers and platforms accused of monopolistic conduct. For example, the case increases the risk that any online marketplace with exclusive rights to (...)

Send a message